Advertisement

Journal of Neuro-Oncology

, Volume 105, Issue 3, pp 591–600 | Cite as

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

  • Philippe MetellusEmail author
  • Carole Colin
  • David Taieb
  • Eric Guedj
  • Isabelle Nanni-Metellus
  • Andre Maues de Paula
  • Cécile Colavolpe
  • Stephane Fuentes
  • Henry Dufour
  • Marylin Barrie
  • Olivier Chinot
  • L’Houcine Ouafik
  • Dominique Figarella-Branger
CLINICAL STUDY – PATIENT STUDY

Abstract

Mutations in the gene encoding isocitrate dehydrogenase enzyme isoforms 1 (IDH1) and 2 (IDH2) have recently been identified in a large proportion of glial tumors of the CNS, but their mechanistic role in tumor development remains unclear. Here, we assessed the actual impact of IDH1 and IDH2 mutations in patients harboring WHO grade II and III gliomas. We sequenced IDH1 at codon 132 and IDH2 at codon 172 in 33 patients with WHO grade II and III gliomas who benefited from a preoperative 18F-FDG positron emission tomography (PET). Immunohistochemical expression of Hypoxia Inducible Factor-1alpha (HIF-1α), Carbonic Anhydrase IX (CAIX), Glucose Transporter 1 (GLUT1) and Caspase 3 active form (CASP3) along with the R132HIDH1 mutation was assessed in all cases as well as 1p/19q deletion status and p53 expression. HIF-1α expression was found in 15% of IDH-mutated compared to 7.7% of IDH-nonmutated tumors (P = 0.954). Also, GLUT-1 positive staining was found in 5% of IDH-mutated and in 7.1% of IDH-nonmutated tumors (P = 0.794). Finally, CA-IX expression was found in 15% of IDH-mutated and in 7.7% of IDH-nonmutated tumors (P = 0.484). The combined expression of these three hypoxic markers was found in two WHO grade III tumors, one of which was IDH-mutated whereas the other was IDH-nonmutated (P = 0.794). In IDH-mutated tumors, the median SUVmax ratio was 2.24 versus 2.15 in IDH-nonmutated tumors (P = 0.775). Together, these data question the actual relationship between IDH mutation status and in vivo hypoxic biomarkers expression in WHO grade II and III gliomas.

Keywords

Active caspase 3 Carbonic anhydrase IX Glucose transporter 1 Isocitrate dehydrogenase-1(IDH1) Hypoxia-inducible factor 1 

Notes

Acknowledgments

We are grateful to F. Frassineti and D. Intagliata for excellent technical assistance, and to C. Bequet-Boucard and C. Courdy for providing clinical information regarding the patients. This work was supported was supported by grants from INSERM (CRO2–UMR911), the INCA (Procan), the Association pour la Recherche sur les Tumeurs Cérébrales (ARTC-Sud), and the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC).

References

  1. 1.
    Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602PubMedCrossRefGoogle Scholar
  2. 2.
    Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7–11PubMedCrossRefGoogle Scholar
  3. 3.
    Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812PubMedCrossRefGoogle Scholar
  4. 4.
    Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773PubMedCrossRefGoogle Scholar
  5. 5.
    Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154PubMedCrossRefGoogle Scholar
  6. 6.
    van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597–1604PubMedCrossRefGoogle Scholar
  7. 7.
    Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718PubMedCrossRefGoogle Scholar
  8. 8.
    Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729PubMedCrossRefGoogle Scholar
  9. 9.
    Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261–265PubMedCrossRefGoogle Scholar
  10. 10.
    Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744PubMedCrossRefGoogle Scholar
  11. 11.
    Ronnebaum SM, Ilkayeva O, Burgess SC, Joseph JW, Lu D, Stevens RD, Becker TC, Sherry AD, Newgard CB, Jensen MV (2006) A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J Biol Chem 281:30593–30602PubMedCrossRefGoogle Scholar
  12. 12.
    Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, Van Noorden CJ (2010) The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119:487–494PubMedCrossRefGoogle Scholar
  13. 13.
    Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234PubMedCrossRefGoogle Scholar
  14. 14.
    Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344PubMedCrossRefGoogle Scholar
  15. 15.
    De Witte O, Lefranc F, Levivier M, Salmon I, Brotchi J, Goldman S (2000) FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 49:157–163PubMedCrossRefGoogle Scholar
  16. 16.
    Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39:778–785PubMedGoogle Scholar
  17. 17.
    Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237PubMedCrossRefGoogle Scholar
  18. 18.
    Bouvier C, Roll P, Quilichini B, Metellus P, Calisti A, Gilles S, Chinot O, Fina F, Martin PM, Figarella-Branger D (2004) Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies. J Neurooncol 68:141–149PubMedCrossRefGoogle Scholar
  19. 19.
    Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606–2618PubMedCrossRefGoogle Scholar
  20. 20.
    Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMedGoogle Scholar
  21. 21.
    Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol 118:469–474PubMedCrossRefGoogle Scholar
  22. 22.
    Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058–1066PubMedCrossRefGoogle Scholar
  23. 23.
    Williams SC, Karajannis MA, Chiriboga L, Golfinos JG, von Deimling A, Zagzag D (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 121:279–281PubMedCrossRefGoogle Scholar
  24. 24.
    Frezza C, Tennant DA, Gottlieb E (2010) IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 17:7–9PubMedCrossRefGoogle Scholar
  25. 25.
    Matsumoto K, Obara N, Ema M, Horie M, Naka A, Takahashi S, Imagawa S (2009) Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model. Cancer Sci 100:1639–1647PubMedCrossRefGoogle Scholar
  26. 26.
    Schlisio S (2009) Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. J Cell Mol Med 13:4104–4112PubMedCrossRefGoogle Scholar
  27. 27.
    Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14:1983–1991PubMedGoogle Scholar
  28. 28.
    Fu Y, Huang R, Du J, Yang R, An N, Liang A (2010) Glioma-derived mutations in IDH: from mechanism to potential therapy. Biochem Biophys Res Commun 397:127–130PubMedCrossRefGoogle Scholar
  29. 29.
    Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12:83–91PubMedCrossRefGoogle Scholar
  30. 30.
    Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102:932–941PubMedCrossRefGoogle Scholar
  31. 31.
    Nakamura H, Masutani H, Yodoi J (2006) Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer. Semin Cancer Biol 16:444–451PubMedCrossRefGoogle Scholar
  32. 32.
    Kobayashi T, Masumoto J, Tada T, Nomiyama T, Hongo K, Nakayama J (2007) Prognostic significance of the immunohistochemical staining of cleaved caspase-3, an activated form of caspase-3, in gliomas. Clin Cancer Res 13:3868–3874PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Philippe Metellus
    • 1
    • 2
    • 3
    • 8
    Email author
  • Carole Colin
    • 2
    • 3
  • David Taieb
    • 4
  • Eric Guedj
    • 4
  • Isabelle Nanni-Metellus
    • 5
  • Andre Maues de Paula
    • 6
  • Cécile Colavolpe
    • 6
  • Stephane Fuentes
    • 1
  • Henry Dufour
    • 1
  • Marylin Barrie
    • 7
  • Olivier Chinot
    • 2
    • 3
    • 7
  • L’Houcine Ouafik
    • 2
    • 3
    • 5
  • Dominique Figarella-Branger
    • 2
    • 3
    • 6
  1. 1.Hôpital de la Timone, Service de NeurochirurgieAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  2. 2.INSERM, UMR 911MarseilleFrance
  3. 3.Faculté de MédecineAix-Marseille UniversitéMarseilleFrance
  4. 4.Hôpital de la Timone, Service Central de Biophysique et Médecine nucléaireAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  5. 5.Laboratoire de Transfert D’oncologie BiologiqueAP-HMMarseilleFrance
  6. 6.Hôpital de la Timone, Service d’Anatomie Pathologique et de NeuropathologieAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  7. 7.Hôpital de la Timone, Unité de NeurooncologieAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  8. 8.Service de NeurochirurgieHôpital de la TIMONECedex MarseilleFrance

Personalised recommendations